609 related articles for article (PubMed ID: 25312765)
1. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
[TBL] [Abstract][Full Text] [Related]
2. Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: A population-based analysis of 6271 cases.
Hallet J; Law CH; Karanicolas PJ; Saskin R; Liu N; Singh S
Cancer; 2015 Jul; 121(13):2214-21. PubMed ID: 25823667
[TBL] [Abstract][Full Text] [Related]
3. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
Allan B; Davis J; Perez E; Lew J; Sola J
Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
[TBL] [Abstract][Full Text] [Related]
4. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome.
Panzuto F; Merola E; Rinzivillo M; Partelli S; Campana D; Iannicelli E; Pilozzi E; Mercantini P; Rossi M; Capurso G; Scarpa A; Cascinu S; Tomassetti P; Falconi M; Delle Fave G
Pancreas; 2014 Mar; 43(2):212-8. PubMed ID: 24518498
[TBL] [Abstract][Full Text] [Related]
5. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
6. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.
Gosain R; Ball S; Rana N; Groman A; Gage-Bouchard E; Dasari A; Mukherjee S
Cancer; 2020 Feb; 126(4):792-799. PubMed ID: 31714595
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
8. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
9. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of metastases in neuroendocrine tumors.
Riihimäki M; Hemminki A; Sundquist K; Sundquist J; Hemminki K
Int J Cancer; 2016 Dec; 139(12):2679-2686. PubMed ID: 27553864
[TBL] [Abstract][Full Text] [Related]
11. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype.
Hsu C; Rashid A; Xing Y; Chiang YJ; Chagpar RB; Fournier KF; Chang GJ; You YN; Feig BW; Cormier JN
J Surg Oncol; 2013 Feb; 107(2):136-43. PubMed ID: 22767417
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.
Panzuto F; Campana D; Fazio N; Brizzi MP; Boninsegna L; Nori F; Di Meglio G; Capurso G; Scarpa A; Dogliotti L; De Braud F; Tomassetti P; Delle Fave G; Falconi M
Neuroendocrinology; 2012; 96(1):32-40. PubMed ID: 22205326
[TBL] [Abstract][Full Text] [Related]
13. Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center.
Kavecansky J; Wei L; Caronia L; Ramirez MT; Bloomston M; Shah MH
Pancreas; 2015 Mar; 44(2):198-203. PubMed ID: 25411805
[TBL] [Abstract][Full Text] [Related]
14. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.
Modlin IM; Champaneria MC; Chan AK; Kidd M
Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004.
Alsina M; Marcos-Gragera R; Capdevila J; Buxó M; Ortiz RM; Barretina P; Vilardell L; Brunet J; Beltran M; Izquierdo Á
Cancer Epidemiol; 2011 Dec; 35(6):e49-54. PubMed ID: 21840785
[TBL] [Abstract][Full Text] [Related]
17. Prognoses of GEP-NETS with undetermined malignant potentials of their primary sites.
Kudo A; Ban D; Akashi T; Kumagai J; Aihara A; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
Hepatogastroenterology; 2012 Sep; 59(118):1682-6. PubMed ID: 22584425
[TBL] [Abstract][Full Text] [Related]
18. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.
Strosberg JR; Weber JM; Feldman M; Coppola D; Meredith K; Kvols LK
J Clin Oncol; 2013 Feb; 31(4):420-5. PubMed ID: 23248248
[TBL] [Abstract][Full Text] [Related]
19. Surgery for metastatic neuroendocrine tumors with occult primaries.
Bartlett EK; Roses RE; Gupta M; Shah PK; Shah KK; Zaheer S; Wachtel H; Kelz RR; Karakousis GC; Fraker DL
J Surg Res; 2013 Sep; 184(1):221-7. PubMed ID: 23643298
[TBL] [Abstract][Full Text] [Related]
20. Small intestinal neuroendocrine tumors: prognostic factors and survival.
Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
